Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27
Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.
Zivanovic N. et al, (2023), Clin Transl Med, 13
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Frater J. et al, (2021), Lancet HIV, 8, e474 - e485
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).
Jefferies K. et al, (2020), J Infect Dis, 222, S658 - S665
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)
Folegatti PM. et al, (2020), LANCET, 396, 466 - 466
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM. et al, (2020), Lancet, 396, 467 - 478
Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.
Wildenbeest JG. et al, (2020), J Infect Dis
Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant immunisation with PCV13.
Kandasamy R. et al, (2019), J Infect Dis
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.
Jeppesen CA. et al, (2015), J Infect, 71, 43 - 52
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
McQuaid F. et al, (2015), CMAJ, 187, E215 - E223
A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine.
Hamaluba M. et al, (2015), Medicine (Baltimore), 94
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
McQuaid F. et al, (2014), Pediatr Infect Dis J, 33, 760 - 766
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
Snape MD. et al, (2013), CMAJ, 185, E715 - E724
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
Snape MD. et al, (2013), Pediatr Infect Dis J, 32, 1116 - 1121
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial
Snape MD. et al, (2013), Pediatric Infectious Disease Journal, 32, 1116 - 1121